1. Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4
- Author
-
Pulido, Mario A, DerHartunian, Meleeneh Kazarian, Qin, Zhenxia, Chung, Eric M, Kang, Diane S, Woodham, Andrew W, Tsou, Jeffrey A, Klooster, Rinse, Akbari, Omid, Wang, Lina, Kast, W Martin, Liu, Stephen V, Verschuuren, Jan JGM, Aswad, Dana W, and Laird-Offringa, Ite A
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Lung ,Vaccine Related ,Lung Cancer ,Autoimmune Disease ,Cancer ,Rare Diseases ,2.1 Biological and endogenous factors ,Aetiology ,Adult ,Aged ,Amino Acid Sequence ,Animals ,Autoimmunity ,ELAV-Like Protein 4 ,Female ,Humans ,Lung Neoplasms ,Male ,Mice ,Mice ,Knockout ,Middle Aged ,Neurons ,Rabbits ,Small Cell Lung Carcinoma ,Small cell lung cancer ,SCLC ,Isoaspartylation ,Neurosciences ,Neurology & Neurosurgery - Abstract
Autoantibodies against SCLC-associated neuronal antigen ELAVL4 (HuD) have been linked to smaller tumors and improved survival, but the antigenic epitope and mechanism of autoimmunity have never been solved. We report that recombinant human ELAVL4 protein incubated under physiological conditions acquires isoaspartylation, a type of immunogenic protein damage. Specifically, the N-terminal region of ELAVL4, previously implicated in SCLC-associated autoimmunity, undergoes isoaspartylation in vitro, is recognized by sera from anti-ELAVL4 positive SCLC patients and is highly immunogenic in subcutaneously injected mice and in vitro stimulated human lymphocytes. Our data suggest that isoaspartylated ELAVL4 is the trigger for the SCLC-associated anti-ELAVL4 autoimmune response.
- Published
- 2016